Andrx Corporation is a specialty pharmaceutical company engaged in the formulation and commercialization of oral controlled-release generic and brand pharmaceuticals utilizing its proprietary drug delivery technologies. The Andrx Group, with a market capitalization of over $4.5 billion, tracks the performance of the Andrx Corporation and subsidiaries, other than Cybear Group.
In addition, Nasdaq will accelerate the addition of Gilead Sciences, Inc. (Nasdaq: GILD) to the Nasdaq-100 Index to October 4, 2001. The previous announcement indicated that the change will occur on October 5, 2001. Gilead will replace Exodus Communications, Inc. (Nasdaq: EXDSQ).
The Nasdaq-100 Index, launched in January 1985, has risen over 50 percent in the past five years, although past performance is not necessarily indicative of future performance and Index performance does not represent the performance of the Nasdaq-100 Index Tracking Stock. The Nasdaq-100 Index Tracking Stock represents ownership in the Nasdaq-100 Trust. The Trust holds a portfolio of equity securities that compose the Nasdaq-100 Index and aims to provide investment results that generally correspond with its performance.
The Nasdaq Stock Market lists more than 4,300 companies and trades more shares per day than any other U.S. market. For more information about Nasdaq, visit the Nasdaq Web site at www.nasdaq.com or the Nasdaq NewsroomSM Web site at www.nasdaqnews.com.
